<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>SHG-Listed — Portfolio on 6ix</title>
<link>https://6ix.com/p/shg-listed</link>
<description>Top companies trading on SHG, ranked by market cap.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 07:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/portfolio/shg-listed" rel="self" type="application/rss+xml" />
<item>
<title>Neusoft Smart Go and Tencent Cloud Forge Strategic Partnership to Build a New AI-Powered Intelligent Cockpit Ecosystem</title>
<link>https://6ix.com/news/neusoft-smart-go-and-tencent-cloud-forge-strategic-partnership-to-build-a-new-ai-powered-intelligent-cockpit-ecosystem</link>
<guid isPermaLink="true">https://6ix.com/news/neusoft-smart-go-and-tencent-cloud-forge-strategic-partnership-to-build-a-new-ai-powered-intelligent-cockpit-ecosystem</guid>
<pubDate>Thu, 30 Apr 2026 07:00:00 GMT</pubDate>
<description>At Auto China 2026, Neusoft Smart Go, a subsidiary of Neusoft Corporation (SSE:600718), officially announced its strategic upgrade. The company now aims to become a global leading provider in full-domain upper-body electronics solutions for intelligent vehicles. At the same time, Neusoft Smart Go and Tencent Cloud announced a strategic partnership. Aligning with "AI-defined vehicles" trend, the two parties will focus on key areas such as intelligent cockpits, on-device AI large model application</description>
</item>
<item>
<title>Haier Biomedical Drives Global Leap of Life Science Infrastructure: International Business Hits Record High for 36% of Annual Revenue in 2025</title>
<link>https://6ix.com/news/haier-biomedical-drives-global-leap-of-life-science-infrastructure-international-business-hits-record-high-for-36percent-of-annual-revenue-in-2025</link>
<guid isPermaLink="true">https://6ix.com/news/haier-biomedical-drives-global-leap-of-life-science-infrastructure-international-business-hits-record-high-for-36percent-of-annual-revenue-in-2025</guid>
<pubDate>Thu, 30 Apr 2026 04:27:00 GMT</pubDate>
<description>Haier Biomedical (688139.SH), a global leader in life sciences and medical solutions, has officially published its 2025 annual report, posting full‑year revenue of 2.33 billion yuan (USD 340.77 million) with overseas revenue growing 17.9% year-on-year to 840 million yuan (USD 122.85 million), accounting for 36% of total revenue – a record high. Despite a complex global trade environment, Haier Biomedical delivered double‑digit growth across all international business sectors.</description>
</item>
<item>
<title>2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations</title>
<link>https://6ix.com/news/2026-esmo-gc-or-mabwell-to-present-latest-clinical-data-on-9mw2821-for-cervical-cancer-in-oral-and-poster-presentations</link>
<guid isPermaLink="true">https://6ix.com/news/2026-esmo-gc-or-mabwell-to-present-latest-clinical-data-on-9mw2821-for-cervical-cancer-in-oral-and-poster-presentations</guid>
<pubDate>Thu, 30 Apr 2026 04:26:00 GMT</pubDate>
<description>Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that two latest clinical study results of its novel Nectin‑4 targeting ADC (R&D code: 9MW2821) in cervical cancer will be presented respectively as an oral presentation and a poster presentation, at the 2026 European Society for Medical Oncology Gynaecological Cancers (ESMO GC) Annual Congress in Copenhagen, Denmark, June 17–19, 2026.</description>
</item>
<item>
<title>United Imaging Healthcare Releases 2025 ESG Report: Upgraded to MSCI "AA" Rating, Driving Sustainable Development Through Innovation</title>
<link>https://6ix.com/news/united-imaging-healthcare-releases-2025-esg-report-upgraded-to-msci-aa-rating-driving-sustainable-development-through-innovation</link>
<guid isPermaLink="true">https://6ix.com/news/united-imaging-healthcare-releases-2025-esg-report-upgraded-to-msci-aa-rating-driving-sustainable-development-through-innovation</guid>
<pubDate>Wed, 29 Apr 2026 12:00:00 GMT</pubDate>
<description>United Imaging Healthcare (SSE:688271) has released its 2025 Environmental, Social and Governance (ESG) Report, outlining the company's strategic framework, key initiatives, and long-term commitments across sustainability.</description>
</item>
<item>
<title>ESG | HitGen Releases 2025 Sustainability Report</title>
<link>https://6ix.com/news/esg-or-hitgen-releases-2025-sustainability-report</link>
<guid isPermaLink="true">https://6ix.com/news/esg-or-hitgen-releases-2025-sustainability-report</guid>
<pubDate>Wed, 29 Apr 2026 11:00:00 GMT</pubDate>
<description>Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) released its 2025 Sustainability Report on April 29, 2026. This report is the second sustainability report of HitGen, aiming to present the Company's philosophies and policies in environmental, social, and governance ("ESG") areas, as well as its sustainable development practices and performance in the year of 2025, to systematically respond to stakeholder concerns.</description>
</item>
<item>
<title>U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA</title>
<link>https://6ix.com/news/us-fda-grants-priority-review-to-beone-medicines-tevimbra-in-first-line-her2-gea</link>
<guid isPermaLink="true">https://6ix.com/news/us-fda-grants-priority-review-to-beone-medicines-tevimbra-in-first-line-her2-gea</guid>
<pubDate>Wed, 29 Apr 2026 10:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., April 29, 2026--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esoph</description>
</item>
<item>
<title>28.13%, 26.4%! LONGi Sets New World Records for Crystalline Silicon Solar Cell and Module Efficiency</title>
<link>https://6ix.com/news/2813percent-264percent-longi-sets-new-world-records-for-crystalline-silicon-solar-cell-and-module-efficiency</link>
<guid isPermaLink="true">https://6ix.com/news/2813percent-264percent-longi-sets-new-world-records-for-crystalline-silicon-solar-cell-and-module-efficiency</guid>
<pubDate>Wed, 29 Apr 2026 04:39:00 GMT</pubDate>
<description>Recently, LONGi announced two major technological breakthroughs. First, its independently developed Hybrid Interdigitated-Back-Contact (HIBC) solar cell has been certified by the Institute for Solar Energy Research Hamelin (ISFH) in Germany, achieving a photoelectric conversion efficiency of 28.13%. This marks yet another step forward toward the theoretical efficiency limit of crystalline silicon solar cells, following LONGi's previous efficiency record of 28.04% set in January 2026. Second, mod</description>
</item>
<item>
<title>InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE</title>
<link>https://6ix.com/news/innocare-announces-first-patient-dosed-in-phase-iii-trial-of-orelabrutinib-for-sle</link>
<guid isPermaLink="true">https://6ix.com/news/innocare-announces-first-patient-dosed-in-phase-iii-trial-of-orelabrutinib-for-sle</guid>
<pubDate>Wed, 29 Apr 2026 00:37:00 GMT</pubDate>
<description>BEIJING, April 28, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the registrational Phase III clinical trial of novel BTK inhibitor orelabrutinib for the treatment of systemic lupus erythematosus (SLE). This is a randomized, double-blind, placebo-controlled, multicenter Phase III study evaluating the efficacy and safety of</description>
</item>
<item>
<title>Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution</title>
<link>https://6ix.com/news/fosun-pharma-announces-q1-2026-results-net-profit-attributable-to-shareholders-after-deducting-non-recurring-gains-and-losses-increased-by-2196percent-yoy-with-strong-pipeline-execution</link>
<guid isPermaLink="true">https://6ix.com/news/fosun-pharma-announces-q1-2026-results-net-profit-attributable-to-shareholders-after-deducting-non-recurring-gains-and-losses-increased-by-2196percent-yoy-with-strong-pipeline-execution</guid>
<pubDate>Tue, 28 Apr 2026 14:54:00 GMT</pubDate>
<description>On 28 April, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its results for the first quarter of 2026 (the reporting period). During the reporting period, the Company achieved a total revenue of RMB 10,073 million, representing a year-on-year increase of 6.93%. Regarding R&D investment, the Company firmly implemented its innovation transformation strategy. During the reporting period, the R&D expenditure increased to RMB 897 million, increased by 1.59% YoY. While increas</description>
</item>
<item>
<title>Neusoft and AISpeech Forge In-depth Partnership to Jointly Build a Global AI Mobility Ecosystem</title>
<link>https://6ix.com/news/neusoft-and-aispeech-forge-in-depth-partnership-to-jointly-build-a-global-ai-mobility-ecosystem</link>
<guid isPermaLink="true">https://6ix.com/news/neusoft-and-aispeech-forge-in-depth-partnership-to-jointly-build-a-global-ai-mobility-ecosystem</guid>
<pubDate>Tue, 28 Apr 2026 12:46:00 GMT</pubDate>
<description>At Auto China 2026, Neusoft Corporation (SSE:600718) and AISpeech signed a Memorandum of Cooperation (MoC) to jointly develop an AI-powered mobility companion featuring natural conversation and proactive intelligence for the global market, by integrating AISpeech's cutting-edge AI voice interaction technologies into Neusoft's newly launched OneCoreGo® Global In-Vehicle Intelligent Mobility Solution 7.0.</description>
</item>
<item>
<title>Arcera Life Sciences and Fosun Pharma launch long-term collaboration framework</title>
<link>https://6ix.com/news/arcera-life-sciences-and-fosun-pharma-launch-long-term-collaboration-framework</link>
<guid isPermaLink="true">https://6ix.com/news/arcera-life-sciences-and-fosun-pharma-launch-long-term-collaboration-framework</guid>
<pubDate>Tue, 28 Apr 2026 11:37:00 GMT</pubDate>
<description>Arcera Life Sciences ("Arcera"), a global life sciences company headquartered in Abu Dhabi, and Shanghai Fosun Pharmaceutical Group Co., Ltd. ("Fosun Pharma"), an innovation-driven global pharmaceutical and healthcare group, today announced the signing of a Memorandum of Understanding (MoU) to establish a long-term strategic collaboration focused on licensing, technology development, neuroscience innovation and value creation in the global life sciences sector.</description>
</item>
<item>
<title>Ping An Reports Steady 7.6% Growth in Operating Profit Attributable to Shareholders of the Parent Company in Q1 2026, Life & Health NBV Increases 20.8% YoY</title>
<link>https://6ix.com/news/ping-an-reports-steady-76percent-growth-in-operating-profit-attributable-to-shareholders-of-the-parent-company-in-q1-2026-life-and-health-nbv-increases-208percent-yoy</link>
<guid isPermaLink="true">https://6ix.com/news/ping-an-reports-steady-76percent-growth-in-operating-profit-attributable-to-shareholders-of-the-parent-company-in-q1-2026-life-and-health-nbv-increases-208percent-yoy</guid>
<pubDate>Tue, 28 Apr 2026 11:36:00 GMT</pubDate>
<description>Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group"; HKEX: 2318; SSE: 601318) today announced its first quarter financial results for the three months ended March 31, 2026.</description>
</item>
<item>
<title>JCET Reports 42.7% YoY Surge in Q1 2026 Net Profit Attributable to Shareholders</title>
<link>https://6ix.com/news/jcet-reports-427percent-yoy-surge-in-q1-2026-net-profit-attributable-to-shareholders</link>
<guid isPermaLink="true">https://6ix.com/news/jcet-reports-427percent-yoy-surge-in-q1-2026-net-profit-attributable-to-shareholders</guid>
<pubDate>Tue, 28 Apr 2026 09:43:00 GMT</pubDate>
<description>JCET Group (SSE: 600584), a leading global provider of integrated circuit (IC) back-end manufacturing and technology services, today announced its financial results for the first quarter of 2026. For the quarter, the company reported revenue of RMB 9.17 billion, and a net profit attributable to shareholders of RMB 290 million, representing a robust year-over-year growth of 42.7%.</description>
</item>
<item>
<title>GAC Launches AION UT Production in Austria, Deepening European Localization Strategy</title>
<link>https://6ix.com/news/gac-launches-aion-ut-production-in-austria-deepening-european-localization-strategy</link>
<guid isPermaLink="true">https://6ix.com/news/gac-launches-aion-ut-production-in-austria-deepening-european-localization-strategy</guid>
<pubDate>Tue, 28 Apr 2026 09:36:00 GMT</pubDate>
<description>GAC has reached a major milestone in its European expansion with the Start of Production and roll-off of its AION UT at Magna's facility in Austria.</description>
</item>
<item>
<title>CNOOC Limited Achieves Strong Start with Dual Growth in Production and Performance in Q1 2026</title>
<link>https://6ix.com/news/cnooc-limited-achieves-strong-start-with-dual-growth-in-production-and-performance-in-q1-2026</link>
<guid isPermaLink="true">https://6ix.com/news/cnooc-limited-achieves-strong-start-with-dual-growth-in-production-and-performance-in-q1-2026</guid>
<pubDate>Tue, 28 Apr 2026 09:23:00 GMT</pubDate>
<description>CNOOC Limited ("the Company", SEHK: 00883 (HKD counter) and 80883 (RMB counter), SSE: 600938) today announced its operating results for the first quarter of 2026. The Company continued to increase reserve and production, while pursue effective cost control and efficiency enhancement. Net production of oil and gas and net profit attributable to equity shareholders both grew strongly.</description>
</item>
<item>
<title>Neusoft and HERE Deepen Strategic Collaboration to Forge an AI-Powered, One-Stop Intelligent Mobility Solution</title>
<link>https://6ix.com/news/neusoft-and-here-deepen-strategic-collaboration-to-forge-an-ai-powered-one-stop-intelligent-mobility-solution</link>
<guid isPermaLink="true">https://6ix.com/news/neusoft-and-here-deepen-strategic-collaboration-to-forge-an-ai-powered-one-stop-intelligent-mobility-solution</guid>
<pubDate>Tue, 28 Apr 2026 07:43:00 GMT</pubDate>
<description>During Auto China 2026, Neusoft Corporation (SSE:600718) and HERE Technologies signed a new Memorandum of Understanding (MOU) to strengthen their strategic cooperation. The two parties announced to establish in-depth partnership and regard each other as Strategic Preferred Partners. By integrating Neusoft's global navigation and mobility product solutions and worldwide deployment expertise with HERE's world-leading map data and location services, they aim to provide global automakers with an AI-</description>
</item>
<item>
<title>Segway Navimow Reaches 1 million Units in Global Cumulative Mass Production</title>
<link>https://6ix.com/news/segway-navimow-reaches-1-million-units-in-global-cumulative-mass-production</link>
<guid isPermaLink="true">https://6ix.com/news/segway-navimow-reaches-1-million-units-in-global-cumulative-mass-production</guid>
<pubDate>Tue, 28 Apr 2026 07:00:00 GMT</pubDate>
<description>Global robotic lawn mower leader Segway Navimow has produced it's one millionth unit. The organization held a ceremony at its research and development and manufacturing base in China to celebrate the milestone. The announcement comes as Navimow launches its new production line in Malaysia, providing a solid foundation for global supply chain stability and delivery efficiency.</description>
</item>
<item>
<title>Joyson Electronics Announces Q1 2026 Results: Strong Orders of RMB 27.5 billion, Net Profit Attributable to Shareholders up Nearly 20% YoY</title>
<link>https://6ix.com/news/joyson-electronics-announces-q1-2026-results-strong-orders-of-rmb-275-billion-net-profit-attributable-to-shareholders-up-nearly-20percent-yoy</link>
<guid isPermaLink="true">https://6ix.com/news/joyson-electronics-announces-q1-2026-results-strong-orders-of-rmb-275-billion-net-profit-attributable-to-shareholders-up-nearly-20percent-yoy</guid>
<pubDate>Mon, 27 Apr 2026 23:56:00 GMT</pubDate>
<description>Joyson Electronics (699.HK) announced financial results for Q1 2026 on April 27. Revenue for the period reached approximately RMB 13.8 billion, profit attributable to shareholders was approximately RMB 400 million, up around 18.1% YoY. Fresh orders reached RMB 27.5 billion, significantly outperforming RMB 15.7 billion in the same period last year.</description>
</item>
<item>
<title>WuXi AppTec Delivers Strong Revenue and Profit Growth in Q1 2026</title>
<link>https://6ix.com/news/wuxi-apptec-delivers-strong-revenue-and-profit-growth-in-q1-2026</link>
<guid isPermaLink="true">https://6ix.com/news/wuxi-apptec-delivers-strong-revenue-and-profit-growth-in-q1-2026</guid>
<pubDate>Mon, 27 Apr 2026 09:03:00 GMT</pubDate>
<description>WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first quarter ending March 31, 2026 ("Reporting Period"):</description>
</item>
<item>
<title>China Eastern Airlines Launches First Direct Route Linking Vienna with Northwest China</title>
<link>https://6ix.com/news/china-eastern-airlines-launches-first-direct-route-linking-vienna-with-northwest-china</link>
<guid isPermaLink="true">https://6ix.com/news/china-eastern-airlines-launches-first-direct-route-linking-vienna-with-northwest-china</guid>
<pubDate>Mon, 27 Apr 2026 05:55:00 GMT</pubDate>
<description>SHANGHAI, April 27, 2026--China Eastern Airlines (CEAir) has inaugurated a new nonstop route connecting Vienna, Austria, and Xi'an, capital of northwest China's Shaanxi Province, marking the first direct air link between Austria and northwest China.</description>
</item>
<item>
<title>Eyebright Medical Releases Its 2025 Annual Report and Sustainability Report</title>
<link>https://6ix.com/news/eyebright-medical-releases-its-2025-annual-report-and-sustainability-report</link>
<guid isPermaLink="true">https://6ix.com/news/eyebright-medical-releases-its-2025-annual-report-and-sustainability-report</guid>
<pubDate>Mon, 27 Apr 2026 01:00:00 GMT</pubDate>
<description>Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", "the Company", Stock Code: 688050.SH, together with its subsidiaries collectively referred to as "the Group") announced yesterday its annual report and sustainability report for the period ended 31 December 2025 (the "Reporting Period").</description>
</item>
<item>
<title>Neusoft Showcases Full-Stack & Global Innovations at Auto China 2026</title>
<link>https://6ix.com/news/neusoft-showcases-full-stack-and-global-innovations-at-auto-china-2026</link>
<guid isPermaLink="true">https://6ix.com/news/neusoft-showcases-full-stack-and-global-innovations-at-auto-china-2026</guid>
<pubDate>Sun, 26 Apr 2026 11:24:00 GMT</pubDate>
<description>At Auto China 2026, Neusoft Corporation (SSE: 600718) hosted a press conference on April 25th and announced three key strategic moves: the iteration of Neusoft OneCoreGo® Global In-Vehicle Intelligent Mobility Solution 7.0, the launch of Neusoft NAGIC.AI Cockpit Software Platform, and the strategic upgrade of its subsidiary, Neusoft Smart Go. By leveraging full-stack technology and a global ecosystem to drive innovation and empowerment, Neusoft is transforming vehicles into proactive, connected</description>
</item>
<item>
<title>LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency</title>
<link>https://6ix.com/news/longi-ecolife-series-module-top-taiyangnews-global-ranking-ushering-in-the-25percent-era-of-photovoltaic-efficiency</link>
<guid isPermaLink="true">https://6ix.com/news/longi-ecolife-series-module-top-taiyangnews-global-ranking-ushering-in-the-25percent-era-of-photovoltaic-efficiency</guid>
<pubDate>Sat, 25 Apr 2026 08:04:00 GMT</pubDate>
<description>Taiyang News, a globally authoritative photovoltaic media outlet, officially released its April 2026 edition of the "TOP SOLAR MODULES LISTING". LONGi's EcoLife series modules (LR7-54HJD-510M), built on HIBC technology, have firmly claimed the top spot with a mass production efficiency of 25%. This milestone marks international recognition of LONGi's innovation strength in the back-contact (BC) technology pathway and ushers in a new "25%+" era for PV module efficiency.</description>
</item>
<item>
<title>Shanghai Electric Highlights AI-Driven Integration of Energy and Industry at Hannover Messe 2026</title>
<link>https://6ix.com/news/shanghai-electric-highlights-ai-driven-integration-of-energy-and-industry-at-hannover-messe-2026</link>
<guid isPermaLink="true">https://6ix.com/news/shanghai-electric-highlights-ai-driven-integration-of-energy-and-industry-at-hannover-messe-2026</guid>
<pubDate>Fri, 24 Apr 2026 01:14:00 GMT</pubDate>
<description>Shanghai Electric (SEHK: 02727, SSE: 601727), a global leader in providing integrated solutions for the energy and industrial sectors, is exhibiting at Hannover Messe 2026 under the theme of "Interlocking Energy and Industry," showcasing its green energy products, integrated energy solutions, and AI-enabled industrial application scenarios.</description>
</item>
<item>
<title>InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability</title>
<link>https://6ix.com/news/innocare-releases-2026-q1-results-strong-revenue-growth-and-sustained-profitability</link>
<guid isPermaLink="true">https://6ix.com/news/innocare-releases-2026-q1-results-strong-revenue-growth-and-sustained-profitability</guid>
<pubDate>Thu, 23 Apr 2026 13:20:00 GMT</pubDate>
<description>BEIJING, April 23, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced its results and business highlights for the first quarter of 2026 as of 31 March 2026. Over the past decade, InnoCare has achieved remarkable results. 2026 marks the beginning of the Company’s next golden decade of development. Driven by its outstanding performance in 2025, the Company continued its rapid progress in the first quarter of 2026, increasing its investment in innovation, commercial</description>
</item>
<item>
<title>GAC INTERNATIONAL and ALLUR Group Sign KD Production Industrial Cooperation Agreement to Advance Localized Production and Deepen Strategic Presence in the CIS Market</title>
<link>https://6ix.com/news/gac-international-and-allur-group-sign-kd-production-industrial-cooperation-agreement-to-advance-localized-production-and-deepen-strategic-presence-in-the-cis-market</link>
<guid isPermaLink="true">https://6ix.com/news/gac-international-and-allur-group-sign-kd-production-industrial-cooperation-agreement-to-advance-localized-production-and-deepen-strategic-presence-in-the-cis-market</guid>
<pubDate>Thu, 23 Apr 2026 08:42:00 GMT</pubDate>
<description>In February 2026, GAC INTERNATIONAL and ALLUR Group, a leading automotive manufacturing and distribution enterprise in Kazakhstan, officially signed a KD production industrial cooperation agreement in Guangzhou.</description>
</item>
<item>
<title>Ping An Releases 2025 Sustainability Report, Unveils "SIMPLE" Framework to Drive Long-Term Value Creation</title>
<link>https://6ix.com/news/ping-an-releases-2025-sustainability-report-unveils-simple-framework-to-drive-long-term-value-creation</link>
<guid isPermaLink="true">https://6ix.com/news/ping-an-releases-2025-sustainability-report-unveils-simple-framework-to-drive-long-term-value-creation</guid>
<pubDate>Thu, 23 Apr 2026 07:19:00 GMT</pubDate>
<description>Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or "the Group"; HKEX: 2318/82318; SSE: 601318) released its 2025 Sustainability Report, introducing for the first time its "SIMPLE" sustainability framework, which demonstrates how the Group embeds sustainability deeply into its core businesses through six strategic pillars to create long-term value for customers, employees, shareholders, and society.</description>
</item>
<item>
<title>2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations</title>
<link>https://6ix.com/news/2026-asco-or-mabwell-to-present-latest-clinical-data-on-9mw2821-combined-with-toripalimab-for-urothelial-carcinoma-in-oral-and-poster-presentations</link>
<guid isPermaLink="true">https://6ix.com/news/2026-asco-or-mabwell-to-present-latest-clinical-data-on-9mw2821-combined-with-toripalimab-for-urothelial-carcinoma-in-oral-and-poster-presentations</guid>
<pubDate>Thu, 23 Apr 2026 07:02:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that two latest clinical study results of its Nectin-4-targeting ADC 9MW2821 in combination with toripalimab for urothelial carcinoma will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA from May 29 to June 2, 2026 (local time), as an oral presentation and a poster presentation, respectively.</description>
</item>
<item>
<title>Trinasolar Introduces Vertex N G3 Module to South Korea, Supporting High-Efficiency and Bankable Solar Deployment</title>
<link>https://6ix.com/news/trinasolar-introduces-vertex-n-g3-module-to-south-korea-supporting-high-efficiency-and-bankable-solar-deployment</link>
<guid isPermaLink="true">https://6ix.com/news/trinasolar-introduces-vertex-n-g3-module-to-south-korea-supporting-high-efficiency-and-bankable-solar-deployment</guid>
<pubDate>Thu, 23 Apr 2026 06:04:00 GMT</pubDate>
<description>Trinasolar, a global leader in smart solar and energy storage solutions, has introduced its latest high-power module, the Vertex N G3, to the South Korea market. The module leverages Trinasolar's advanced n-type i-TOPCon Ultra technology, delivering a maximum power output of 760W.</description>
</item>
<item>
<title>GigaDevice GD32F5HC Series MCU Grand Launch, Advancing High‑Performance Innovation for HMI and IoT Edge Solutions</title>
<link>https://6ix.com/news/gigadevice-gd32f5hc-series-mcu-grand-launch-advancing-highperformance-innovation-for-hmi-and-iot-edge-solutions</link>
<guid isPermaLink="true">https://6ix.com/news/gigadevice-gd32f5hc-series-mcu-grand-launch-advancing-highperformance-innovation-for-hmi-and-iot-edge-solutions</guid>
<pubDate>Wed, 22 Apr 2026 13:00:00 GMT</pubDate>
<description>SINGAPORE, April 22, 2026--GigaDevice, a leading global supplier of semiconductor devices, today announced the official launch of the GD32F5HC series 32‑bit general‑purpose microcontrollers. Designed with compact size, high frequency operation, large memory, and strong security, while also offering ultra‑low power consumption and rich peripheral configuration, the new series expands the GD32 Arm® Cortex®‑M33 portfolio and delivers a powerful platform for next‑generation HMI and IoT Edge solution</description>
</item>
<item>
<title>BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6</title>
<link>https://6ix.com/news/beone-medicines-to-announce-first-quarter-2026-financial-results-on-may-6</link>
<guid isPermaLink="true">https://6ix.com/news/beone-medicines-to-announce-first-quarter-2026-financial-results-on-may-6</guid>
<pubDate>Wed, 22 Apr 2026 10:01:00 GMT</pubDate>
<description>SAN CARLOS, Calif., April 22, 2026--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.</description>
</item>
<item>
<title>Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth</title>
<link>https://6ix.com/news/hengrui-pharma-reports-q1-2026-results-with-revenue-and-net-profit-growth</link>
<guid isPermaLink="true">https://6ix.com/news/hengrui-pharma-reports-q1-2026-results-with-revenue-and-net-profit-growth</guid>
<pubDate>Wed, 22 Apr 2026 09:40:00 GMT</pubDate>
<description>Hengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14 billion, up 12.98% year-over-year, while net profit attributable to shareholders increased by 21.78% to RMB 2.28 billion. Innovative drugs remained the key growth driver, generating RMB 4.53 billion in revenue, up 25.75% year-over-year and accounting for 61.69% of total pharmaceutical sales.</description>
</item>
<item>
<title>Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine</title>
<link>https://6ix.com/news/case-report-of-mabwells-nectin-4-targeting-adc-9mw2821-in-cervical-cancer-published-in-the-new-england-journal-of-medicine</link>
<guid isPermaLink="true">https://6ix.com/news/case-report-of-mabwells-nectin-4-targeting-adc-9mw2821-in-cervical-cancer-published-in-the-new-england-journal-of-medicine</guid>
<pubDate>Wed, 22 Apr 2026 02:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industrial chain, announced that a recent clinical case report on its self-developed novel Nectin-4 ADC (bulumtatug fuvedotin, R&D code: 9MW2821) for the treatment of cervical cancer has been published in The New England Journal of Medicine (NEJM, Impact Factor: 78.5), a leading international medical journal.</description>
</item>
<item>
<title>ADOCIA Announces Full Year 2025 Financial Results and Provides a Corporate and Financial Update</title>
<link>https://6ix.com/news/adocia-announces-full-year-2025-financial-results-and-provides-a-corporate-and-financial-update-3</link>
<guid isPermaLink="true">https://6ix.com/news/adocia-announces-full-year-2025-financial-results-and-provides-a-corporate-and-financial-update-3</guid>
<pubDate>Tue, 21 Apr 2026 18:30:00 GMT</pubDate>
<description>LYON, France, April 21, 2026--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, publishes its annual financial results as of December 31, 2025. The consolidated statements contained herein were approved by Adocia’s board of directors on April 20, 2026. Audit procedures have been completed and the audit report</description>
</item>
<item>
<title>Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026</title>
<link>https://6ix.com/news/dizal-to-report-key-progress-in-its-nsclc-portfolio-with-two-oral-presentations-and-a-poster-during-asco-2026</link>
<guid isPermaLink="true">https://6ix.com/news/dizal-to-report-key-progress-in-its-nsclc-portfolio-with-two-oral-presentations-and-a-poster-during-asco-2026</guid>
<pubDate>Tue, 21 Apr 2026 16:45:00 GMT</pubDate>
<description>Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, today announced that new clinical data from its non-small cell lung cancer (NSCLC) pipeline will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2 in Chicago. The presentations will feature the company's investigational assets ZEGFROVY® (sunvozertinib), golidocitinib, and DZD6008, highlighted by two oral pres</description>
</item>
<item>
<title>Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety</title>
<link>https://6ix.com/news/preclinical-data-of-novel-b7-h3-adc-icp-b794-unveiled-at-2026-aacr-demonstrating-superior-anti-tumor-activity-and-safety</link>
<guid isPermaLink="true">https://6ix.com/news/preclinical-data-of-novel-b7-h3-adc-icp-b794-unveiled-at-2026-aacr-demonstrating-superior-anti-tumor-activity-and-safety</guid>
<pubDate>Tue, 21 Apr 2026 10:00:00 GMT</pubDate>
<description>BEIJING, April 21, 2026 (GLOBE NEWSWIRE) -- At the 2026 American Association for Cancer Research (AACR) Annual Meeting, InnoCare Pharma (HKEX: 9969; SSE: 688428) presented preclinical data of its novel B7-H3 targeted ADC ICP-B794. The research results were presented in the form of a poster at the AACR Annual Meeting (Abstract Code: LB355). ICP-B794 is a B7-H3 targeted ADC with a novel linker-payload. It demonstrated potent anti-tumor activity in preclinical tumor models and a significantly large</description>
</item>
<item>
<title>Hisense Ignites the Countdown to the FIFA World Cup 2026™, Showcasing Next-Generation Home Entertainment and Smart Living</title>
<link>https://6ix.com/news/hisense-ignites-the-countdown-to-the-fifa-world-cup-2026tm-showcasing-next-generation-home-entertainment-and-smart-living</link>
<guid isPermaLink="true">https://6ix.com/news/hisense-ignites-the-countdown-to-the-fifa-world-cup-2026tm-showcasing-next-generation-home-entertainment-and-smart-living</guid>
<pubDate>Tue, 21 Apr 2026 09:51:00 GMT</pubDate>
<description>Hisense, a leading brand in global consumer electronics and home appliances, today marks the 50-day countdown to the FIFA World Cup 2026™ with the launch of its global campaign. As a three-time FIFA World Cup official sponsor, having first partnered with FIFA in 2018 and continuing in 2022, Hisense once again leverages the world's biggest sporting stage to spotlight a new generation of flagship products designed to elevate how fans watch, live, and connect.</description>
</item>
<item>
<title>Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time</title>
<link>https://6ix.com/news/mabwell-passes-on-site-gmp-inspection-by-regulatory-authority-of-pics-member-country-jordan-for-the-first-time</link>
<guid isPermaLink="true">https://6ix.com/news/mabwell-passes-on-site-gmp-inspection-by-regulatory-authority-of-pics-member-country-jordan-for-the-first-time</guid>
<pubDate>Tue, 21 Apr 2026 02:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned subsidiary, T-mab, has successfully passed the on-site GMP inspection conducted by the Jordan Food and Drug Administration (JFDA). The inspection covered two denosumab injections: 9MW0311 (Prolia® biosimilar) and 9MW0321 (Xgeva® biosimilar). The facility was granted conclusion of "Compliance" from JFDA. This marks Mabwell's inaugural recognition by a regulat</description>
</item>
<item>
<title>Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026</title>
<link>https://6ix.com/news/junshi-biosciences-presents-results-from-js207-pd-1vegf-bsab-phase-2-combo-studies-and-js212-egfrher3-adc-fih-phase-12-study-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/news/junshi-biosciences-presents-results-from-js207-pd-1vegf-bsab-phase-2-combo-studies-and-js212-egfrher3-adc-fih-phase-12-study-at-aacr-2026</guid>
<pubDate>Mon, 20 Apr 2026 21:00:00 GMT</pubDate>
<description>SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that early clinical results from four studies across its innovative pipeline were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, featuring: the recombinant humanized anti-EGFR/HER3 bisp</description>
</item>
<item>
<title>Shanghai Electric Reports Strong 2025 Performance, New Orders Hit Record High</title>
<link>https://6ix.com/news/shanghai-electric-reports-strong-2025-performance-new-orders-hit-record-high</link>
<guid isPermaLink="true">https://6ix.com/news/shanghai-electric-reports-strong-2025-performance-new-orders-hit-record-high</guid>
<pubDate>Fri, 17 Apr 2026 14:13:00 GMT</pubDate>
<description>Shanghai Electric (SEHK: 02727, SSE: 601727) announced its 2025 performance results, reporting revenue of RMB 126.68 billion (USD 18.58 billion), marking a 9.03% year-on-year increase. The net profit attributable to shareholders of the listed company reached RMB 1.206 billion (USD 176.92 million), a surge of 60.37% year-on-year. The total value of new orders received throughout the year amounted to RMB 172.81 billion (USD 25.35 billion), up 12.50% year-on-year, hitting a record high.</description>
</item>
<item>
<title>WeRide and GAC Debut First Co-Developed Vehicle Aion N60 Powered by WRD 3.0</title>
<link>https://6ix.com/news/weride-and-gac-debut-first-co-developed-vehicle-aion-n60-powered-by-wrd-30</link>
<guid isPermaLink="true">https://6ix.com/news/weride-and-gac-debut-first-co-developed-vehicle-aion-n60-powered-by-wrd-30</guid>
<pubDate>Thu, 16 Apr 2026 12:36:00 GMT</pubDate>
<description>GUANGZHOU, China, April 16, 2026 (GLOBE NEWSWIRE) -- GAC Aion today officially launched pre-sales for the Aion N60, a new smart urban SUV powered by WeRide Driving (WeRide WRD* 3.0), WeRide’s one-stage end-to-end ADAS (Advanced Driver Assistance System) solution. The Aion N60 has intelligent driving features across the entire lineup, bringing advanced assisted driving to a broad consumer market. With WeRide WRD 3.0, the Aion N60 delivers full-scenario, full-function ADAS capabilities, covering u</description>
</item>
<item>
<title>Huaqin Technology Launches Hong Kong IPO with Blue-Chip Cornerstone Line-up Securing 50% Allocation</title>
<link>https://6ix.com/news/huaqin-technology-launches-hong-kong-ipo-with-blue-chip-cornerstone-line-up-securing-50percent-allocation</link>
<guid isPermaLink="true">https://6ix.com/news/huaqin-technology-launches-hong-kong-ipo-with-blue-chip-cornerstone-line-up-securing-50percent-allocation</guid>
<pubDate>Wed, 15 Apr 2026 12:01:00 GMT</pubDate>
<description>Huaqin Technology (603296.SH) has formally kicked off the global offering of its H shares on the Hong Kong Exchange, with trading expected to commence on April 23, positioning the company as an "A+H"-listed intelligent product platform.</description>
</item>
<item>
<title>Ping An Bank Upgraded to AAA in MSCI ESG Ratings, Ranking Among the Leading Global Banks</title>
<link>https://6ix.com/news/ping-an-bank-upgraded-to-aaa-in-msci-esg-ratings-ranking-among-the-leading-global-banks</link>
<guid isPermaLink="true">https://6ix.com/news/ping-an-bank-upgraded-to-aaa-in-msci-esg-ratings-ranking-among-the-leading-global-banks</guid>
<pubDate>Wed, 15 Apr 2026 06:32:00 GMT</pubDate>
<description>Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or "the Group"; HKEX: 2318/82318; SSE: 601318) is pleased to announce that its subsidiary, Ping An Bank Co., Ltd. ("Ping An Bank" or "the Bank"; SZSE: 000001), has been upgraded to AAA, the highest rating, in the latest MSCI ESG Ratings.</description>
</item>
<item>
<title>Designed in Milan, Built for Europe: GAC Debuts the AION UT Electric Hatchback</title>
<link>https://6ix.com/news/designed-in-milan-built-for-europe-gac-debuts-the-aion-ut-electric-hatchback</link>
<guid isPermaLink="true">https://6ix.com/news/designed-in-milan-built-for-europe-gac-debuts-the-aion-ut-electric-hatchback</guid>
<pubDate>Tue, 14 Apr 2026 12:01:00 GMT</pubDate>
<description>GAC today launches its second model in the fully electric AION product line in Europe's capital of design Milan: the electric hatchback AION UT. The model was developed by GAC and co-designed by the GAC's Advanced Design Centre in Milan. AION UT will first go on sale in Finland, Greece, Poland and Portugal this quarter. Other European markets will follow in Q3.</description>
</item>
<item>
<title>No More Fuel Anxiety! AION UT Debuts in Australia, Setting a New Benchmark for Urban Electric Vehicles</title>
<link>https://6ix.com/news/no-more-fuel-anxiety-aion-ut-debuts-in-australia-setting-a-new-benchmark-for-urban-electric-vehicles</link>
<guid isPermaLink="true">https://6ix.com/news/no-more-fuel-anxiety-aion-ut-debuts-in-australia-setting-a-new-benchmark-for-urban-electric-vehicles</guid>
<pubDate>Fri, 10 Apr 2026 08:33:00 GMT</pubDate>
<description>On April 10, the highly anticipated 2026 Melbourne Motor Show grandly kicked off. GAC made a strong appearance with four vehicle models across its product lines — GAC, AION, — highlighting its leading strength in new energy and intelligent technologies, while reinforcing its image of "Tech-Driven GAC, Advancing Global Reach with a Full-Chain Ecosystem". At the show, GAC officially announced the launch of its global strategic model, the AION UT, in Australia. This marks not only a milestone in GA</description>
</item>
<item>
<title>JCET Releases 2025 Annual Report, Posts Record-High Full-Year Revenue and Higher Profit Before Tax</title>
<link>https://6ix.com/news/jcet-releases-2025-annual-report-posts-record-high-full-year-revenue-and-higher-profit-before-tax</link>
<guid isPermaLink="true">https://6ix.com/news/jcet-releases-2025-annual-report-posts-record-high-full-year-revenue-and-higher-profit-before-tax</guid>
<pubDate>Thu, 09 Apr 2026 15:41:00 GMT</pubDate>
<description>Today, JCET Group (SSE: 600584), a leading global provider of integrated circuit (IC) back-end manufacturing and technology services, released its 2025 Annual Report. JCET reported record full-year revenue of RMB 38.87 billion in 2025, up 8.1% year-on-year. Profit before tax (PBT) totaled RMB 1.74 billion, up 5.4% year-on-year, and net profit attributable to shareholders reached RMB 1.57 billion.</description>
</item>
<item>
<title>Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide</title>
<link>https://6ix.com/news/gan-and-lee-pharmaceuticals-signs-exclusive-license-agreement-with-jw-pharmaceutical-the-leading-south-korean-pharma-to-advance-the-global-commercialization-of-the-innovative-glp-1-receptor-agonist-bofanglutide</link>
<guid isPermaLink="true">https://6ix.com/news/gan-and-lee-pharmaceuticals-signs-exclusive-license-agreement-with-jw-pharmaceutical-the-leading-south-korean-pharma-to-advance-the-global-commercialization-of-the-innovative-glp-1-receptor-agonist-bofanglutide</guid>
<pubDate>Thu, 09 Apr 2026 13:00:00 GMT</pubDate>
<description>Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", SSE: 603087) announced the signing of an exclusive licensing agreement with JW Pharmaceutical, a leading pharmaceutical company in South Korea. Under the agreement, the two parties will collaborate on the clinical development, regulatory filing, and commercialization in South Korea of Bofanglutide Injection, a bi-weekly (once every two weeks) Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) independently discovered and develope</description>
</item>
<item>
<title>CNOOC Limited Released 2025 Environmental, Social and Governance Report</title>
<link>https://6ix.com/news/cnooc-limited-released-2025-environmental-social-and-governance-report</link>
<guid isPermaLink="true">https://6ix.com/news/cnooc-limited-released-2025-environmental-social-and-governance-report</guid>
<pubDate>Thu, 09 Apr 2026 09:36:00 GMT</pubDate>
<description>CNOOC Limited ("the Company", SEHK: 00883 (HKD counter) and 80883 (RMB counter), SSE: 600938) released its 2025 Environmental, Social and Governance (ESG) Report in Hong Kong today.</description>
</item>
<item>
<title>Ping An Launches "Service Year 2026": Upgrades AI‑Powered Express Service and Global Emergency Assistance</title>
<link>https://6ix.com/news/ping-an-launches-service-year-2026-upgrades-aipowered-express-service-and-global-emergency-assistance</link>
<guid isPermaLink="true">https://6ix.com/news/ping-an-launches-service-year-2026-upgrades-aipowered-express-service-and-global-emergency-assistance</guid>
<pubDate>Thu, 09 Apr 2026 09:36:00 GMT</pubDate>
<description>Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or "the Group"; HKEX: 2318/82318; SSE: 601318) today announced major upgrades to its AI‑powered Express Service and Global Emergency Assistance, marking the launch of its "Service Year 2026" initiative.</description>
</item>
<item>
<title>Hisense "How We Host: 2026" Report Finds More Than Half of Americans Host Monthly as Expectations Rise and the Home Becomes the Center of Every Big Moment</title>
<link>https://6ix.com/news/hisense-how-we-host-2026-report-finds-more-than-half-of-americans-host-monthly-as-expectations-rise-and-the-home-becomes-the-center-of-every-big-moment</link>
<guid isPermaLink="true">https://6ix.com/news/hisense-how-we-host-2026-report-finds-more-than-half-of-americans-host-monthly-as-expectations-rise-and-the-home-becomes-the-center-of-every-big-moment</guid>
<pubDate>Wed, 08 Apr 2026 13:05:00 GMT</pubDate>
<description>Americans are not just gathering at home more often, they are raising the bar for what it means to host. Hisense, a globally recognized leader in home appliances and consumer electronics, a pioneer in RGB MiniLED display technology, and an Official Sponsor of the FIFA World Cup 2026™, commissioned its "How We Host: 2026" report to better understand this shift. The findings reveal that 93% of Americans say the overall experience matters when entertaining, signaling a move toward more thoughtful,</description>
</item>
</channel>
</rss>